Novo Nordisk’s next obesity battlefront: Winning beyond America

Novo Nordisk has told CNBC how it is preparing to go "all in" on launching its Wegovy pill outside the U.S, as the battle for dominance of the weight-loss market goes global.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.